Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)
- Previous Close
19.280 - Open
19.760 - Bid 19.220 x --
- Ask 19.260 x --
- Day's Range
19.120 - 19.600 - 52 Week Range
9.410 - 20.500 - Volume
373,000 - Avg. Volume
755,983 - Market Cap (intraday)
6.13B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
58.36 - EPS (TTM)
0.330 - Earnings Date --
- Forward Dividend & Yield 0.11 (0.55%)
- Ex-Dividend Date Jun 4, 2025
- 1y Target Est
18.69
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People's Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, intracranial stenosis, carotid artery, and intracranial access devices. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products. In addition, the company provides technical consultation and services, as well as imports materials. The company was formerly known as Zhejiang Zylox Medical Device Co., Ltd. and changed its name to Zylox-Tonbridge Medical Technology Co., Ltd. in March 2021. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Hangzhou, the People's Republic of China.
www.zyloxtb.comRecent News: 2190.HK
View MorePerformance Overview: 2190.HK
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2190.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2190.HK
View MoreValuation Measures
Market Cap
6.21B
Enterprise Value
4.94B
Trailing P/E
59.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.67
Price/Book (mrq)
1.88
Enterprise Value/Revenue
5.92
Enterprise Value/EBITDA
33.02
Financial Highlights
Profitability and Income Statement
Profit Margin
12.81%
Return on Assets (ttm)
0.66%
Return on Equity (ttm)
3.26%
Revenue (ttm)
782.48M
Net Income Avi to Common (ttm)
100.26M
Diluted EPS (ttm)
0.330
Balance Sheet and Cash Flow
Total Cash (mrq)
1.28B
Total Debt/Equity (mrq)
2.93%
Levered Free Cash Flow (ttm)
--